MedTrace Logo

Identifying Therapeutic Targets of Accelerated Sarcopenia

NCT03118050 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

The proposed research is designed to identify the mechanisms that can accelerate loss of muscle size, strength and physical function in type 2 diabetes and with hospitalization in older persons. About ⅓ of older Americans have type 2 diabetes, and about ⅓ of the hospitalizations in the USA involve persons older than 65 year of age. The proposed research is relevant to the part of NIH's mission that pertains to development of the fundamental knowledge that will improve health and reduce the burdens of disability, because this work will provide the fundamental evidence to identify new targets for the development of innovative treatments to slow down muscle loss and disability in our aging society.

Conditions

Interventions

BEHAVIORAL

Resistance exercise training

Supervised resistance exercise training, 3 times a week for 3 months

BEHAVIORAL

Bed rest

Bed rest for 5 days, followed by standard rehabilitation for 2 days

BEHAVIORAL

Intensive physical therapy

Intensive weight bearing PT, daily, during bed rest

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Elena Volpi, MD, PhD · UTMB

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-28
Primary Completion
2023-08-21
Completion
2023-08-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03118050 on ClinicalTrials.gov